YL211

YL211 is a next-generation antibody-drug conjugate (ADC) that specifically targets c-Met (also known as mesenchymal-epithelial transition factor), a receptor tyrosine kinase overexpressed or mutated in many tumor cell types. By binding to c-Met on the surface of cancer cells, YL211 delivers a cytotoxic payload directly to these cells, inhibiting their proliferation and survival. The drug also induces a bystander effect on neighboring tumor cells, further enhancing its anti-tumor activity. Developed for the treatment of advanced solid tumors, YL211 is currently being evaluated in Phase 1 clinical trials[1][2][3][4][5][7].

Other names

anti-c-Met ADC YL211anti-c-Met/TOP1i ADC YL211anti-c-Met/TOP1i antibody-drug conjugate YL211